EliotAshbyBrintonMDFAHA, FNLA
Endocrinology • Salt Lake City, UTDiabetes, Lipid Metabolism
President, Utah Lipid Center; President Atherometabolism Institute
Dr. Brinton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Utah Lipid Center
421 S Wakara Way, Ste 121
Salt Lake City, UT 84108Phone+1 801-403-7530Fax+1 801-606-7279
Summary
- Dr. Eliot Brinton is an endocrinologist in Salt Lake City, UT and is affiliated with Intermountain Medical Center. He received his medical degree from University of Utah School of Medicine and has been in practice 39 years. He also speaks multiple languages, including Spanish. He specializes in lipid metabolism and is experienced in obesity and obesity-related disorders, lipid metabolism disorders, diabetes mellitus type 2, ldl apheresis, and estrogen replacement.
Education & Training
University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism, 1981 - 1984
Duke University HospitalResidency, Internal Medicine, 1978 - 1981
University of Utah School of MedicineClass of 1978
Certifications & Licensure
AZ State Medical License 1997 - Present
UT State Medical License 2003 - 2026
NC State Medical License 1978 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Clinical LipidologyBoard Certified Clinical Lipidologist
Awards, Honors, & Recognition
- Robert I. Levy Award Lipoprotein Kinetics and Metabolism Society, 2012
- Merit Review Award Veterans Administration, 1998
Clinical Trials
- KEEPS Cognitive and Affective Study Start of enrollment: 2007 May 01
- Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors Start of enrollment: 2006 Jan 01
- Study of Trilipix Effects on Lipids and Arteries Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Polycystic ovary syndrome: A review of diagnosis and management, with special focus on atherosclerotic cardiovascular disease prevention.Merle L Myerson, Rodis D Paparodis, Robert C Block, Dean G Karalis, Guy Mintz
Journal of Clinical Lipidology. 2024-05-09 - 5 citationsLipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.Michael Szarek, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson
Journal of the American College of Cardiology. 2024-04-23 - 3 citationsIcosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.Neila Sayah, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Terry A Jacobson
European Heart Journal. 2024-04-01
Press Mentions
Prescription Omega-3 Fatty Acid Medications Effectively Lower High TriglyceridesAugust 21st, 2019
Amarin’s Vascepa, AstraZeneca’s Epanova Theoretical Cardiovascular Risk Reduction Class Effect Possibly StifledJune 17th, 2019
Finding a Path Forward: The Continued Unmet Medical Need in FCSJanuary 30th, 2019- Join now to see all
Grant Support
- Estrogen Replacement Therapy In Post-Menopausal WomenNational Center For Research Resources1995–1997
- High Density Lipoprotein (HDL) Turnover StudiesNational Center For Research Resources1994–1995
- Regulation Of HDL Levels By Genetic And Environmental FactorsNational Center For Research Resources1987–1992
- Molecular Genetic Control Of HDL Apoprotein MetabolismNational Heart, Lung, And Blood Institute1991
- Molecular Genetic Control Of HDL Apoprotein MetabolismNational Heart, Lung, And Blood Institute1987–1990
- Diet And Drug Effects On HDL MetabolismNational Center For Research Resources1985–1986
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
